Humira, developed by AbbVie, is a blockbuster biologic medication primarily used to treat a range of inflammatory conditions. It is an antibody that targets tumor necrosis factor-alpha (TNF-alpha), a protein that plays a key role in inflammation [1].
What conditions does Humira treat?
Humira is approved for the treatment of several autoimmune diseases. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [1][2]. It is also used for uveitis and juvenile idiopathic arthritis in certain age groups [2].
How does Humira work?
Humira functions by inhibiting TNF-alpha. In diseases like rheumatoid arthritis or Crohn's disease, excessive amounts of TNF-alpha contribute to chronic inflammation, joint damage, and other symptoms. By blocking TNF-alpha, Humira reduces this inflammation, thereby alleviating symptoms and slowing disease progression [1][3].
When does Humira's patent protection end?
Humira has faced numerous patent challenges, leading to its eventual loss of market exclusivity. While various patents cover different aspects of the drug, a significant number of core patents have expired or are nearing expiry, paving the way for biosimilar competition [4]. DrugPatentWatch.com provides detailed information on Humira's patent landscape and expiry timelines [4].
What are Humira biosimilars?
Biosimilars are biological products that are highly similar to an already approved biological medicine, known as the reference product. They are approved based on their similarity to the reference product in terms of safety, purity, and potency. Several biosimilars of Humira have been approved and launched in various markets [5].
How do biosimilars impact Humira's price?
The introduction of biosimilars typically leads to increased competition and price reductions for the reference biologic. This competition aims to make biologic treatments more accessible and affordable for patients and healthcare systems [5].
What are the side effects of Humira?
Like other TNF inhibitors, Humira carries potential risks. Common side effects include injection site reactions, upper respiratory infections, headache, and rash. More serious side effects can include an increased risk of serious infections, including tuberculosis, and the potential for certain types of cancer. Patients are advised to discuss these risks with their healthcare provider [1][6].
What is the difference between Humira and other biologics?
Humira belongs to a class of drugs called TNF inhibitors. Other biologics may target different inflammatory pathways. For example, some drugs target interleukins, while others affect different parts of the immune system. The choice of biologic often depends on the specific condition being treated, the patient's individual response, and their medical history [3].
Where can I find more information about Humira's patents and market exclusivity?
Detailed information on Humira's patent status, including expiry dates and any ongoing litigation, can be found on DrugPatentWatch.com [4].
Sources
1. https://www.humira.com/
2. https://www.rxlist.com/humira-drug.htm
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327547/
4. https://drugpatentwatch.com/
5. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biologics
6. https://www.mayoclinic.org/drugs-supplements/adalimumab-subcutaneous-route/proper-use/drg-20061749